Jeremiah Ladd, MD
Physical Medicine & Rehabilitation · Omaha, NENPI 1760680011
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 15 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 9 manufacturers reported payments, led by Si-bone, Inc. at 34.9% of the total. Reporting peaked in 2019 at $324 and has fallen 89.1% since, to $35 in 2025.
Across 15 payments — averaging $36.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Si-bone, Inc.$191
- Merz North America, Inc.$139
- Globus Medical$54
- Baxter Healthcare$48
- Amgen$38
- Conetic Solutions, Inc.$29
- plus $48 from 3 others
What the payments were for
- Food & beverage$546100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Si-bone, Inc. | 5 | $191 |
| Merz North America, Inc. | 1 | $139 |
| Globus Medical | 1 | $54 |
| Baxter Healthcare | 1 | $48 |
| Amgen | 3 | $38 |
| Conetic Solutions, Inc. | 1 | $29 |
| Heron Therapeutics, Inc. | 1 | $22 |
| Vertex | 1 | $19 |
| Forte Bio-pharma LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEOMIN$139
- iFuse Implant$125
How this compares
$546 in reported general payments places this provider in the 70th percentile of 57 physical medicine & rehabilitation providers in Nebraska.
See all physical medicine & rehabilitation providers in Nebraska →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Gabapentin | 429 | $8,974 |
| Duloxetine Hcl | 88 | $1,271 |
| Celecoxib | 38 | $1,152 |
| Methylprednisolone | 90 | $598 |
| Cyclobenzaprine Hcl | 34 | $537 |
| Pregabalin | 19 | $307 |
| Methocarbamol | 14 | $296 |
| Meloxicam | 81 | $234 |
| Tizanidine Hcl | 41 | $210 |
| Tramadol Hcl | 19 | $161 |
| Naproxen | 11 | $73 |
| Diclofenac Sodium | 12 | $47 |
Paid to pharmacies, not to this prescriber.
Other physical medicine & rehabilitation in Omaha
- Kurt GoldOmaha$8K
- Jeremy GallantOmaha$2K
- Bo CuiOmaha$2K
- Thomas FrancoOmaha$2K
- Zachary GustinOmaha$1K
- James KultOmaha$1K
- Sonia SchneiderOmaha$973
- Grant LanghoferOmaha$652
- Michael WeaverOmaha$573
- Alexander D'angeloOmaha$514
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.